Library — CHDR

Search

Filter

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

De Kam PJ, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P

International journal of clinical pharmacology and therapeutics, 2014 Feb; 52(3):227-36

View publication
Reply: Comment on 'Chemotherapy for testicular cancer induces acute alterations in diastolic heart function'.

van Schinkel LD, Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, Smit JW, de Roos A, Osanto S, Lamb HJ

British journal of cancer, 2014 Jan; 110(1):265

View publication
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.

de Kam PJ, El Galta R, Kruithof AC, Fennema H, van Lierop MJ, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD

International journal of clinical pharmacology and therapeutics, 2013 Nov; 51(12):976-85

View publication
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.

van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013 Sep; 62(4):796-800

View publication
Chemotherapy for testicular cancer induces acute alterations in diastolic heart function.

van Schinkel LD, Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, Smit JW, de Roos A, Osanto S, Lamb HJ

British journal of cancer, 2013 Aug; 109(4):891-6

View publication
Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.

Kluft C, Meijer P, Kret R, Burggraaf J

International journal of laboratory hematology, 2013 Jul; 35(4):379-84

View publication
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.

Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, van Steijn-van Tol AQ, Rosendaal FR, Osanto S

British journal of cancer, 2013 Jul; 109(1):60-7

View publication
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Heuberger JA, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, Burggraaf J, Cohen AF

British journal of clinical pharmacology, 2013 May; 75(6):1406-21

View publication
Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.

Klein RH, van der Vorst MM, de Wilde RB, Hogenbirk K, de Kam ML, Burggraaf J

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013 Mar; 24(3):327-31

View publication

«
1
2
3
4
5
6
7
8
...
12
13
»